Standout Papers

The International Classification of Headache Disorders: 2nd... 1990 2026 2002 2014 4.2k
  1. The International Classification of Headache Disorders: 2nd edition (2003)
    Jes Olesen, Peter J. Goadsby et al. The Lancet Neurology
  2. A Report on the Journal 2004 (2004)
    Peter J. Goadsby Cephalalgia
  3. Migraine — Current Understanding and Treatment (2002)
    Peter J. Goadsby, Richard B. Lipton et al. New England Journal of Medicine
  4. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache (1990)
    Peter J. Goadsby, Lars Edvinsson et al. Annals of Neurology
  5. Pathophysiology of Migraine: A Disorder of Sensory Processing (2017)
    Peter J. Goadsby, Philip R. Holland et al. Physiological Reviews
  6. Calcitonin Gene–Related Peptide Receptor Antagonist BIBN 4096 BS for the Acute Treatment of Migraine (2004)
    Jes Olesen, Hans‐Christoph Diener et al. New England Journal of Medicine
  7. The trigeminovascular system and migraine: Studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats (1993)
    Peter J. Goadsby, Lars Edvinsson Annals of Neurology
  8. Hypothalamic activation in cluster headache attacks (1998)
    Arne May, Anish Bahra et al. The Lancet
  9. New Appendix Criteria Open for a Broader Concept of Chronic Migraine (2006)
    Jes Olesen, M.G. Bousser et al. Cephalalgia
  10. Oral triptans (serotonin 5-HT1B/1D agonists) in acute migraine treatment: a meta-analysis of 53 trials (2001)
    Michel D. Ferrari, Krista I Roon et al. The Lancet
  11. Release of vasoactive peptides in the extracerebral circulation of humans and the cat during activation of the trigeminovascular system (1988)
    Peter J. Goadsby, Lars Edvinsson et al. Annals of Neurology
  12. A Controlled Trial of Erenumab for Episodic Migraine (2017)
    Peter J. Goadsby, Uwe Reuter et al. New England Journal of Medicine
  13. EFNS guideline on the drug treatment of migraine – revised report of an EFNS task force (2009)
    Stefan Evers, Judit Áfra et al. European Journal of Neurology
  14. Guidelines for Controlled Trials of Drugs in Migraine: Second Edition (2000)
    Peer Tfelt‐Hansen, Gilbert Block et al. Cephalalgia
  15. Fremanezumab for the Preventive Treatment of Chronic Migraine (2017)
    Stephen D. Silberstein, David W. Dodick et al. New England Journal of Medicine
  16. Human in vivo evidence for trigeminovascular activation in cluster headache Neuropeptide changes and effects of acute attacks therapies (1994)
    Peter J. Goadsby, Lars Edvinsson Brain
  17. A review of paroxysmal hemicranias, SUNCT syndrome and other short- lasting headaches with autonomic feature, including new cases (1997)
    Peter J. Goadsby Brain
  18. Disability, HRQoL and resource use among chronic and episodic migraineurs: Results from the International Burden of Migraine Study (IBMS) (2010)
    TK Wilcox, AN Manack et al. Cephalalgia
  19. Galcanezumab in chronic migraine (2018)
    Holland C. Detke, Peter J. Goadsby et al. Neurology
  20. Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine (2018)
    David W. Dodick, Stephen D. Silberstein et al. JAMA
  21. Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study (2018)
    Uwe Reuter, Peter J. Goadsby et al. The Lancet
  22. Efficacy and safety of eptinezumab in patients with chronic migraine (2020)
    Richard B. Lipton, Peter J. Goadsby et al. Neurology
  23. Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial (2019)
    Robert Croop, Peter J. Goadsby et al. The Lancet
  24. Migraine (2022)
    Michel D. Ferrari, Peter J. Goadsby et al. Nature Reviews Disease Primers
  25. Guidelines of the International Headache Society for controlled trials of preventive treatment of chronic migraine in adults (2018)
    Cristina Tassorelli, Hans‐Christoph Diener et al. Cephalalgia
  26. Rimegepant, an Oral Calcitonin Gene–Related Peptide Receptor Antagonist, for Migraine (2019)
    Richard B. Lipton, Robert Croop et al. New England Journal of Medicine
  27. Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial (2020)
    Robert Croop, Richard B. Lipton et al. The Lancet
  28. Migraine: disease characterisation, biomarkers, and precision medicine (2021)
    Messoud Ashina, Gisela M. Terwindt et al. The Lancet
  29. Atogepant for the Preventive Treatment of Migraine (2021)
    Jessica Ailani, Richard B. Lipton et al. New England Journal of Medicine
  30. Safety, tolerability, and efficacy of zavegepant 10 mg nasal spray for the acute treatment of migraine in the USA: a phase 3, double-blind, randomised, placebo-controlled multicentre trial (2023)
    Richard B. Lipton, Robert Croop et al. The Lancet Neurology
  31. Migraine: from pathophysiology to treatment (2023)
    Francesca Puledda, Peter J. Goadsby et al. Journal of Neurology
  32. Atogepant for the preventive treatment of chronic migraine (PROGRESS): a randomised, double-blind, placebo-controlled, phase 3 trial (2023)
    Patricia Pozo‐Rosich, Jessica Ailani et al. The Lancet

Immediate Impact

9 by Nobel laureates 16 from Science/Nature 130 standout
Sub-graph 1 of 16

Citing Papers

Computational design of soluble and functional membrane protein analogues
2024 StandoutNatureNobel
Trigeminal ganglion neurons are directly activated by influx of CSF solutes in a migraine model
2024 StandoutScience
33 intermediate papers

Works of Peter J. Goadsby being referenced

Safety, tolerability, and efficacy of zavegepant 10 mg nasal spray for the acute treatment of migraine in the USA: a phase 3, double-blind, randomised, placebo-controlled multicentre trial
2023 Standout
Migraine aura symptoms: Duration, succession and temporal relationship to headache
2015
and 66 more

Author Peers

Author Last Decade Papers Cites
Peter J. Goadsby 53390 35051 23562 917 62.1k
Michel D. Ferrari 21217 10711 7471 522 29.0k
Lars Edvinsson 16686 9955 13288 958 40.6k
David W. Dodick 22431 14568 9024 526 27.5k
Stephen D. Silberstein 20708 13188 9332 426 25.2k
Messoud Ashina 15761 8813 6113 428 18.9k
Giuseppe Nappi 9559 5169 5602 595 19.2k
Lenore J. Launer 12877 1911 12728 605 42.1k
Marcelo E. Bigal 14785 8648 5327 268 16.9k
Richard Mayeux 19443 988 20883 514 51.2k
Troels S. Jensen 4313 5394 28552 546 48.6k

All Works

Loading papers...

Rankless by CCL
2026